Bevacizumab and breast cancer: the E2100 outlier.

Keywords

Moringa, Shelf life, Food science, Food quality, Biotechnology

References

• Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.文孝 石田, 孝子 仁科, 孝次 村越 — 2010
• Overall Survival: A Gold Standard in Search of a Surrogate: The Value of Progression-Free Survival and Time to Progression as End Points of Drug EfficacySen Hong Zhuang, Liang Xiu, Yusri Elsayed — 2009
• Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).Nicholas J. Robert, Véronique Dièras, John A. Glaspy — 2009
• Progression-Free Survival: Gaining on Overall Survival as a Gold Standard and AcceleratingDrug DevelopmentDavid Lebwohl, Andrea Kay, William J. Berg — 2009
• Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC).Joyce O’Shaughnessy, Véronique Dièras, John A. Glaspy — 2009
• Progression-Free Survival Is Simply a Measure of a Drug’s Effect While Administered and Is Not a Surrogate for Overall SurvivalJulia Wilkerson, Tito Fojo — 2009
• Stable Disease Is Not Preferentially Observed With Targeted Therapies and as Currently Defined Has Limited Value in Drug DevelopmentTatiana Vidaurre, Julia Wilkerson, Richard Simon — 2009
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.Kathy D. Miller, Molin Wang, Julie R. Gralow — 2007
• Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.Bryan P. Schneider, Μolin Wang, Milan Radovich — 2008
• Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.David Miles, Arlene Chan, Luc Dirix — 2010
• RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC).Nicholas J. Robert, Véronique Dièras, John A. Glaspy — 2009

Cited by

• VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.Daniele Minardi, Guendalina Lucarini, Matteo Santoni — 2013
• Bevacizumab in breast cancer: fundamental questions remain.David W. Miles — 2013
• UK guidance document: treatment of metastatic breast cancer.Robert E. Coleman, Gianfilippo Bertelli, Tara Beaumont — 2012
• Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast CancerRodrigo Dienstmann, Felipe Ades, Kamal S. Saini — 2012
• Targeting the Tumor Microenvironment: Focus on AngiogenesisFengjuan Fan, Alexander Schimming, Dirk Jaeger — 2011
• Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence.Lauren Willis, Azza B. El‐Remessy, Payaningal R. Somanath — 2011
• Predictive value of loci in VEGF pathway genes in bevacizumab treatment.Mauro Moroni — 2012
• Targeting angiogenesis in metastatic breast cancer.Sangeetha M. Reddy, Michael J.M. Raffin, Virginia Kaklamani — 2012
• Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after BevacizumabLee S. Schwartzberg, Kurt W. Tauer, Robert C. Hermann — 2013
• VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.Diether Lambrechts, Bart Claes, Paul Delmar — 2012
• Drug Development: Portals of DiscoverySusan E. Bates, Laleh Amiri‐Kordestani, Giuseppe Giaccone — 2012
• Subconjunctival Bevacizumab for Primary Pterygium Excision; a Randomized Clinical TrialReza Razeghinejad, Mohammad Banifatemi — 2014
• Clinical experience with ramucirumab: outcomes in breast cancerGeraldine O’Sullivan Coyne, Mauricio Burotto — 2014
• 5-Fluorouracil vs avastin as adjunct to conjunctival autograft in the surgical treatment of pterygiumCharles O. Bekibele, Tarela Sarimiye, A Ogundipe — 2016
• Bevacizumab — eine endlose GeschichteK. Mross — 2012
• The intriguing role of bevacizumab in advanced breast cancer - The search continuesJosé Pablo Leone, Ricardo H. Álvarez — 2012
• Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter studyMingxia Jiang, Bin Shao, Donggui Wan — 2023
• Avastin withdrawal symptomsF. Lynce, S. Swain — 2012

Related papers

• Moringa oleifera: A Review of the Medical Evidence for Its Nutritional, Therapeutic, and Prophylactic Properties. Part 1.Jed W. Fahey, Barbara Lewis — 2005
• Nutritional characterization of Moringa (Moringa oleifera Lam.) leavesMoyo Busani, Johan Patrick, Hugo Arnold — 2011
• EFFECT OF DRIED MORINGA (MORINGA OLEIFERA LAM) LEAVES ON RHEOLOGICAL, MICROSTRUCTURAL, NUTRITIONAL, TEXTURAL AND ORGANOLEPTIC CHARACTERISTICS OF COOKIESK. B. Dachana, Jyotsna Rajiv, D. Indrani — 2010
• Effect of Moringa oleifera Leaf Powder Supplementation on Some Quality Characteristics of Wheat BreadAbraham I. Sengev, Joseph Oneh Abu, Dick I. Gernah — 2013
• Moringa oleifera as a food fortificant: Recent trends and prospectsAdewumi T. Oyeyinka, Samson A. Oyeyinka — 2016
• Quality characteristics of bread and cookies enriched with debittered Moringa oleifera seed flourB. S. Ogunsina, C. Radha, D. Indrani — 2011
• Proximate Composition and Sensory Properties of Moringa Fortified Maize-OgiVictoria Funmilayo — 2015
• Moringa oleifera: a food plant with multiple medicinal usesFarooq Anwar, Sajid Latif, Muhammad Ashraf — 2007
• An Evaluation of Nutritional and Sensory Qualities of Wheat - Moringa CakeFL Kolawole, MA Balogun, DO Opaleke — 2013